By far the two most common prostate diseases are prostatitis and benign hyperplasia (BPH). Prostatitis can be complicated by BPH or associated with periodic exacerbations. Drug therapy is an important component in the overall treatment of prostate diseases. In addition, treatment often ends in loss due to improper therapy, missed medications, and, when the condition is alleviated, ignoring the disease.
Thus, 20-30% of patients are not satisfied with the treatment, do not feel a reduction in the symptoms of urinary disorders and an improvement in the quality of life. Most likely, this is due to an inaccurate assessment of lower urinary tract function in men with BPH and, accordingly, the choice of inadequate treatment.
As you know, prostatitis is acute and chronic (CP), bacterial and abacterial.
Prostatitis in%
- acute bacterial prostatitis - 5-10%;
- chronic bacterial prostatitis - 6-10%;
- chronic abacterial prostatitis - 80-90%, including prostatodin - 20-30%.
The most common is chronic abacterial prostatitis, which must be controlled and prevented in time from worsening with and without BPH.
The main drugs for the treatment of BPH and chronic prostatitis:
- 5a-reductase inhibitors (finasteride, dutasteride);
- a-blockers (doxazosin, tamsulosin);
- phytotherapy (sabali palm extract);
- antibiotics;
- amino acid complexes;
- animal organ extracts (prostate extract);
- entomotherapy drugs (products derived from insects).
At the same time, in 13-30% of the effect from the use of a-blockers does not occur within 3 months of treatment - further therapy with drugs of this group is not advisable.
When prescribing finasteride, the doctor should be prepared for the fact that the most important side effects of the drug: impotence, decreased libido, decreased ejaculate volume can lead to self-withdrawal of the drug by the patient.
Treatment of BPH and prostatitis is an important urological problem, not completely solved.
Frequent exacerbations of CP in the absence of indications for surgery on the prostate gland force the doctor to use additional methods in the treatment of medication. Often, the presence of concomitant CP worsens the course of BPH, because inflammation in 80% of cases is in the prostate gland with benign hyperplasia.
Modern medicine gives us new opportunities to treat CP and BPH and prevent exacerbations.